VivoSeq
Oncology

HR+ Breast Cancer

2

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

HR+ Breast Cancer is an early-stage landscape with 2 programs across 3 companies. The most active players are NiKang Therapeutics, Inc., Fresenius Kabi Oncology Ltd., Novartis.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

NiKang Therapeutics, Inc.

1 program

Phase 1F

Fresenius Kabi Oncology Ltd.

1 program

Phase 1Novartis logo

Novartis

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

Fulvestrant

Fresenius Kabi Oncology Ltd.

Letrozole

Novartis

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/CDK4 Dual Degrader NKT5097 in Adults With Advanced/Metastatic Solid Tumors
Recruiting·NNiKang Therapeutics, Inc.·Phase 1·NCT07029399·361 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)